Cancer drug resistance: a new perspective

References

[1] Coppola S,Danen EHJ,Schmidt T,Giovannetti E.A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer..Drug Resist Updat2017;31:43-51

[2] Caparello C,Garajova I,Le Large TY,Kazemier G,Vasile E.FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer..World J Gastroenterology2016;22:6987-7005 PMCID:PMC4988311

[3] Shachar SS,Jones E.Management of triple-negative breast cancer in older patients: how is it different?.Oncology (Williston Park)2018;32:58-63

[4] Phillips RM,Peters GJ.EO9 (Apaziquone): from the clinic to the laboratory and back again..Brit J Pharmacol2013;168:11-8

[5] Jaramillo AC,Cloos J,Peters GJ.How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?.Cancer Drug Resist2018;1:6-29

[6] Szakács G,Ludwig JA,Gottesman MM.Targeting multidrug resistance in cancer..Nat Rev Drug Discov2006;5:219-34

[7] Dominijanni A.Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations..Cancer Drug Resist2018;1:48-58

[8] Peters GJ,Freemantle S,Codacci-Pisanelli G,Smid K,Calvert AH,McLeod HL,Meijer S,van Groeningen CJ.Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism..Biochim Biophys Acta2002;1587:194-205

[9] Danenberg PV,Johnston PJ,Moser R,Peters GJ.Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action..Crit Rev Oncol Hematol2016;106:118-31

[10] Peters GJ,van Moorsel CJ,Bergman AM.Basis for effective combination cancer chemotherapy with antimetabolites..Pharmacol Ther2000;87:227-53

[11] Grivicich I,Peters GJ.Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer..Braz J Med Biol Res2001;34:1087-103

[12] Strickler JH.Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer..Oncologist2012;17:513-24 PMCID:PMC3336830

[13] Van Der Steen N,Rolfo C,Peters GJ.New developments in the management of non-small cell lung cancer, focus on rociletinib: what went wrong?.Onco Targets Ther2016;9:6065-74

[14] Muller IB,Honeywell RJ,Peters GJ.Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib..Expert Rev Anticancer Ther2016;16:147-57

[15] Ballestreri É,de Souza AP,Nabinger DD,Grivicich I.Resistance mechanism to cisplatin in NCI-H460 non-small cell lung cancer cell line: investigating apoptosis, autophagy, and cytogenetic damage..Cancer Drug Resist2018;1:72-81

[16] Gómez VE,Peters GJ.Unraveling the complexity of autophagy: potential therapeutic applications in pancreatic ductal adenocarcinoma..Semin Cancer Biol2015;35:11-9

[17] Sharaf Eldin O,Youssef AR,Maxwell P.Reduction of mitomycin C resistance in human bladder cancer T24 cells by knocking-down ras oncogene..Cancer Drug Resist2018;1:59-71

[18] Uckun FM.Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas..Cancer Drug Resist2018;1:30-47

[19] Gotink KG,Labots M,Dekker H,Rudek MA,Musters RJ,Griffioen AW,Pili R,Verheul HM.Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance..Clin Cancer Res2011;17:7337-46 PMCID:PMC4461037

[20] Da Silva CG,Dekker H.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters..Expert Opin Drug Metab Toxicol2015;11:703-17

[21] Adar Y,Bram EE,van den Bergh H,Sarna T,Griffioen AW.Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers..Cell Death Dis2012;3:e293

[22] Direcks WGE,Proost N,Balzarini J,Lammertsma AA.[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study..Brit J Cancer2008;99:481-7 PMCID:PMC2527810

[23] Gade DR,Yarlagadda RB,Sastry BS.Elucidation of chemosensitization effect of acridones in cancer cell lines: combined pharmacophore modelling, 3D QSAR and molecular dynamics studies..Comp Biol Chem2018;74:63-75

[24] Robert J,Giovannetti E.On the use of pharmacogenetics in cancer treatment and clinical trials..Eur J Cancer2014;50:2532-43

[25] Azijli K,Peters GJ.New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies..Anticancer Res2014;34:1493-505

[26] van de Ven R,van der Heijden JW,de Gruijl TD,Scheper RJ.ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer..J Leukoc Biol2009;86:1075-87

[27] Avan A,Giovannetti E.Role of Akt signaling in resistance to DNA-targeted therapy..World J Clin Oncol2016;7:352-69 PMCID:PMC5056327

[28] Narayanan RS,Brands E,Stalpers LJ,Slotman BJ,Peters GJ.The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures..BMC Cancer2017;17:204 PMCID:PMC5359921

[29] Massihnia D,Funel N,Van Krieken A,Raktoe R,Aicher B,Russo A,Peters GJ.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of AKT inhibitors with gemcitabine in pancreatic cancer..J Hematol Oncol2017;10:9 PMCID:PMC5219723

[30] Kwakman R,De Winter J,Delis-Van Diemen P,Rooimans MA,Carvalho B,Bonjer HJ,Te Velde EA.Tailoring heated intraperitoneal Mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival..Br J Cancer2015;112:851-6 PMCID:PMC4453952

[31] Honeywell RJ,Kathmann I.Transport of six tyrosine kinase inhibitors: active or passive?.2016;4:23-34

[32] Honeywell RJ,Buddha M,Kathman I.Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors..2015;3:51-67